




The relative strengths and weaknesses of Keros Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keros Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 170% points. The greatest weakness of Keros Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 355%, being 142% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	347,293
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,373
Liabilities, Non-Current	13,439
Other Assets	18,598
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	16,949
Other Revenues	151
Property and Equipment	4,134
Research and Development	135,258
Selling, General and Administrative Expense	34,834

Output Variable	Value in 1000 USD
Assets	370,025
Liabilities	37,812
Expenses	170,092
Revenues	151
Stockholders Equity	332,213
Net Income	-152,992
Comprehensive Net Income	-152,992
BaseVar	297,514
ECR before Limited Liability	280%
Economic Capital Ratio	355%